• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    bioAffinity Technologies, Inc. - Common Stock (NQ: BIAF )

    0.9500 UNCHANGED
    Streaming Delayed Price Updated: 12:50 PM EST, Dec 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about bioAffinity Technologies, Inc. - Common Stock

    < Previous 1 2 3 Next >
    Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Set for Continued Expansion in 2025
    From bioAffinity Technologies, Inc.
    Via Business Wire
    Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
    From bioAffinity Technologies, Inc.
    Via Business Wire
    Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
    From bioAffinity Technologies, Inc.
    Via Business Wire
    Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESSWIRE
    bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
    From bioAffinity Technologies, Inc.
    Via Business Wire
    BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESSWIRE
    bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies News Update
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung
    From bioAffinity Technologies, Inc.
    Via Business Wire
    bioAffinity Technologies News Update
    From bioAffinity Technologies, Inc.
    Via Business Wire
    Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies’ Medical and Scientific Advisory Board and Incorporates CyPath® Lung into Medical Practice
    From bioAffinity Technologies, Inc.
    Via Business Wire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.